Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

In two randomised phase 3 studies involving 480 participants aged 12 years and over, ivacaftor/tezacaftor/vanzacaftor was ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...

That's encouraging, considering that Vertex's current top-selling CF drug Trikafta/Kaftrio raked in revenue of $10.2 billion last year. Adding to the excitement, the FDA approved Vertex's acute pain ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...

Members of the International Hearing Society (IHS) are gearing up to celebrate World Hearing Day on March 3, 2025, to raise awareness of hearing healthcare and address the stigma attached to hearing ...

Strong demand for its CF therapy, Trikafta/Kaftrio, delivered $10.2 billion in revenue for the year. We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its ...